Clinical Trials

189 enrolled

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT04236414 2025-04-04

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

16 enrolled

Neoplasms

NCT06686745 2025-01-07

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Recruiting

130 enrolled

Advanced Solid Tumors

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

BreastGenitourinaryGynecologic

70 enrolled 13 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Phase 1 Terminated

24 enrolled

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Classical hematologyGynecologic

98 enrolled

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00782574 2023-12-21

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

57 enrolled

Advanced Solid Tumors

NCT01921140 2022-11-22

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

60 enrolled

Neoplasms

NCT02588105 2022-09-19

AToM

84 enrolled

Advanced Solid Tumours

NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Phase 1 Terminated

44 enrolled

Solid Tumors

NCT03022409 2021-08-10

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

BreastGastrointestinalGenitourinaryGynecologicLymphoid

49 enrolled

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT02511795 2019-11-07

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

128 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02093351 2019-10-02

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

79 enrolled 35 charts

Neoplasms

NCT02430311 2019-07-31

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

36 enrolled 24 charts

Advanced Solid Tumours

NCT02561832 2019-02-20

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Phase 1 Terminated

15 enrolled 8 charts

Breast

Breast Neoplasms

NCT00707707 2018-03-06

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

19 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01813474 2018-01-16

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

23 enrolled 15 charts

Neoplasms

NCT01851265 2017-08-28

D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

32 enrolled

Neoplasms

NCT00710268 2015-01-14

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

18 enrolled

Neoplasm Metastasis

NCT00515866 2013-12-20

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

68 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

48 enrolled

Malignant Solid Tumors

NCT00572364 2009-08-20

Open Label, Dose Escalation Phase I Study of AZD2281

18 enrolled

Neoplasms

NCT00516802 2009-05-15

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

40 enrolled

Dermatologic

Melanoma Neoplasms

NCT00633269 2009-01-14

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

6 enrolled